Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 23, Issue 1, 2005, Pages 31-53

  Krishnan, Kannan ^a,b   Johanson, Gunnar ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

PBPK models; Pharmacokinetics; Risk assessment; Toxicokinetics

Indexed keywords

COMPUTER SIMULATION; MARKOV PROCESSES; MATHEMATICAL MODELS; METABOLISM; MONTE CARLO METHODS; PHARMACOKINETICS; PHYSIOLOGY; RISK ASSESSMENT; TOXIC MATERIALS;

CANCER RISK ASSESSMENT; MULTICHEMICAL EXPOSURE SITUATIONS; MULTICHEMICAL INTERACTIONS; TOXICOKINETIC MODELS;

TUMORS;

BENZENE; CYTOCHROME P450 2E1; DICHLOROMETHANE; FURAN; GLUTATHIONE TRANSFERASE;

ADOLESCENT; ADULT; CANCER RISK; CHEMICAL CARCINOGENESIS; CHILD; CHILDHOOD CANCER; DOSIMETRY; ENVIRONMENTAL EXPOSURE; GENOTYPE; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MODEL; MONTE CARLO METHOD; PROBABILITY; REVIEW; RISK ASSESSMENT; TISSUE DISTRIBUTION; TOXICOKINETICS;

CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; TISSUE DISTRIBUTION;

EID: 17144418176     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-200051856     Document Type: Review

References (75)

1. Wagner JG. History of pharmacokinetics. Pharmacol Ther 1981;12:537-562.
2. Renwick AG. Toxicokinetics-pharmacokinetics in toxicology. In: Principles and Methods of Toxicology (WA. Rayes, Ed.), 2003; Raven Press, New York, 101-147.
3. Clewell HJI, Andersen ME, Barton HA. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ Health Perspect 2002;110(1):85-93.
4. Andersen ME, Dennison JE. Mode of action and tissue dosimetry in current and future risk assessments. Sci Tot Environ 2001;274:3-14.
5. Reitz RH, McDougal JN, Himmelstein MW, Nolan RJ, Schumann AM. Physiologically-based pharmacokinetic modeling with methyl chloroform: Implications for interspecies, high-low dose and dose-route extrapolations. Toxicol Appl Pharmacol 1998a;95:185-199.
6. Reitz RH, McCroskey PS, Park CN, Andersen ME, Gargas ML. Development of a physiologically-based pharmacokinetic model for risk assessment with 1,4-dioxane. Toxicol Appl Pharmacol 1990;105:37-54.
7. Leung HW, Paustenbach DJ. Cancer risk assessment for dioxane based upon a physiologically-based pharmacokinetic modeling approach. Toxicol Lett 1990;51:147-162.
8. Andersen ME, Clewell HJI, Gargas ML, Smith FA, Reitz RH. Physiologically-based pharmacokinetics and risk assessment process for methylene chloride. Toxicol Appl Pharmacol 1987;87:185-205.
9. Fisher JW, Allen BC. Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal 1993;13:87-95.
10. Clewell HJI, Gentry PR, Gearhart JM, Allen BC, Andersen ME. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci Total Environ 2001;274(1-3):37-66.
11. Reitz RH, Gargas ML, Andersen ME, Provan WM, Green TL. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol Appl Pharmacol 1996;137:253-267.
12. Gehring PJ, Watanabe PG, Park CN. Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example-vinyl chloride. Toxicol Appl Pharmacol 1978;44(3):581-591.
13. Haggard HW. The absorption, distribution and elimination of ethyl ether. Analysis of the mechanism of the absorption and elimination of such a gas or vapor as ethyl ether. J Biol Chem 1924;59:753-770.
14. Kety SS. The theory and application of the exchange of inert gas at the lungs. Pharmacol Rev 1951;3:1-41.
15. Mapleson WW. An electric analog for uptake and elimination in man. J Appl Physiol 1963;18:197-204.
16. Fiserova-Bergerova V. Mathematical modeling of inhalation exposure. J Combustion Toxicol 1975;32:201-210.
17. Krishnan K, Andersen ME. Physiologically-based pharmacokinetic modeling in toxicology. In Principles and Methods of Toxicology, (A. W. Hayes, Ed.), Taylor & Francis, Philadelphia, PA, 2001;193-241.
18. Clewell HJI, Andersen ME. Dose, species and route extrapolation using physiologically-based pharmacokinetic models. Drinking Water and Health 1987;8:159-182.
19. Andersen ME, Krewski D, Withey JR. Physiological pharmacokinetics and cancer risk assessment. Cancer Lett 1993;69:1-14.
20. Andersen ME, Krishnan K. Physiologically based pharmacokinetics and cancer risk assessment. Environ Health Perspect 1994;102(Suppl 1):103-108.
21. Melnick RL, Kohn MC. Dose-response analyses of experimental cancer data. Drug Metab Rev 2000;32:193-209.
22. US EPA. Guidelines for Carcinogen Risk Assessment, Final Draft. Washington, US Environmental Protection Agency, Office of Research and Development 2003, NCEA-F-0644.
23. Tardif R, Charest-Tardif G, Brodeur J, Krishnan K. Physiologically-based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol Appl Pharmacol 1997;144:120-134.
24. Jarabek AM, Fisher JW, Rubenstein R, Lipscomb JC, Wills RJ, Vinegar A, McDougal JN. Mechanistic insights aid the search for CFC Substitutes: Risk assessment of HCFC-123 as an example. Risk Analysis 1994;14:231-250.
25. Gerrity TR, Henry CJ, Birnbaum L. Principles of Route-to-Route extrapolation for risk assessment. 1990, New York, Elsevier.
26. Krishnan K, Andersen ME. Physiological modeling and cancer risk assessment. In: New Trends in Pharmacokinetics (A Rescingo and A Thakkur, Eds.), 1991; Plenum Press, NY, 335-354.
27. Kirman CR, Hays SM, Kedderis GL, Gargas ML, Strother DE. Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat. Risk Anal 2000;20(1):135-151.
28. Poet TS, Soelberg JJ, Weitz KK, Mast TJ, Miller AA, Thrall BD, Corley RA. Mode of action and pharmacokinetic studies of 2-butoxyethanol in the mouse with an emphasis on forestomach dosimetry. Toxicol Sci 2003;71:176-189.
29. Reitz RH, Mandrela AL, Corley RA, Quast JF, Gargas ML, Andersen ME, Staats DA, Conolly RB. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically-based pharmacokinetic modeling. Toxicol Appl Pharmacol 1990;105:443-459.
30. Meek ME, Beauchamp R, Long G, Turner L, Walker M. Chloroform: Exposure estimation, hazard characterization, and exposure-response Analysis. J Toxicol Environ Health 2002;5(B):283-334.
31. 1 mice but not Syrian golden hamsters exposed to dichloromethane: Pharmacokinetics and risk assessment with DPX as dosimeter. Fund Appl Toxicol 1996;31:103-116.
32. Schlosser PM, Patrick DL, Conolly RB, Janszen DB, Kimbell JS. Benchmark dose risk assessment for formaldehyde using airflow modeling and a single-compartment, DNA-protein cross-link dosimetry model to estimate human equivalent doses. Risk Analysis 2003;23:473-487.
33. Andersen ME, Sarangapani R, Gentry PR, Clewell HJ, III, Covington, TR, Frederick CB. Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid. Toxicol Sci 1999;57:312-325.
34. Andersen ME, Green T, Frederick CB, Bogdanffy MS. Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regul Toxicol Pharmacol 2002;36:234-245.
35. Cruzen G, Carlson GP, Johnson KA, Andrews LS, Banton MI, Bevan C, Cushman JR. Styrene respiratory tract toxicity and mouse lung tumors are mediated by CYP2F-generated metabolites. Reg Toxicol Pharmacol 2002;35:308-319.
36. Bogdanffy MS, Sarangapani R, Plowchalk DR, Jarabek AM, Andersen ME. A biologically-based risk assessment for vinyl acetate-induced cancer and noncancer inhalation toxicity. Toxicol Sci 1999;51:19-35.
37. Bogdanfy MS, Plowchalk DR, Sarangapani R, Starr TB, Andersen ME. Mode-of-action-based dosimeters for interspecies extrapolation on vinyl acetate inhalation risk. Inhal Toxicol 2001;13:377-396.
38. Reitz RH, Mandrela AL, Park CN, Andersen ME, Guengerich FP. Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PBPK) model for methylene chloride: Implications for risk assessment. Toxicol Lett 1988;43:97-116.
39. Spear RC, Bois FY. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. Environ Health Perspect 1994;102(Suppl.11):61-66.
40. Bois FY, Jackson ET, Pekari K, Smith MT. Population toxicokinetics of benzene. Environ Health Perspect 1996;104(Suppl.6):1405-1411.
41. Bernillon P, Bois FY. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ. Health Perspect Suppl 2000;108:S883-S893.
42. Jonsson F, Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol Appl Pharmacol 2001;174:99-112.
43. Jonsson F, Johanson G. Physiologically-based modeling of the inhalation kinetics of styrène in humans using a Bayesian population approach. Toxicol Appl Pharmacol 2002;179(1):35-49.
44. Wakefield JC, Smith AFM. Bayesian analysis of linear and non-linear population models by using the Gibbs sample. Appl Stat 1994;43:201-221.
45. Jonsson F, Johanson G. The Bayesian population approach to physiological toxicokinetic - toxicodynamic models - an example using the MCSim software. Toxicol Lett 2003;143-150.
46. El-Masri HA, Bell DA, Portier CJ. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol Appl Pharmacol 1999;158:221-230.
47. Ginsberg GL. Assessing cancer risks from short-term exposures in children. Risk Anal 2003;23(1):19-34.
48. Gladtke E. Pharmacokinetics in relation to age. Boll Chim Farm 1973;112:333-341.
49. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66:185-200.
50. Clewell HJI, Teeguarden JG, McDonald T, Sarangapani R, Lawrence GS, Covington TR, Gentry R, Shipp, A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 2002;32(5):329-389.
51. Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health 2001;64(A):453-464.
52. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Delivery Rev 2003;55:667-686.
53. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fund Clin Pharmacol 2003;17:281-299.
54. Price K, Haddad S, Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health 2003;66(Part A):417-433.
55. De Zwart LL, Haenen HEMG, Versantvoort CHM, Wolterink G, Van Engelen JGM, Sips AJAM. Role of biokinetics in risk Assessment of drugs and chemicals in children. Regul Toxicol Pharmacol 2004;39(3):282-309.
56. Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 2004;79:381-393.
57. Ginsberg G, Hattis D, Russ A, Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. J Toxicol Environ Health Part A 2004;67:297-329.
58. Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M, Goble R. Differences in pharmacokinetics between children and adults - II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 2003;23:117-142.
59. Woo Y-T, Di Carlo FJ, Arcos JC, Argus MF, Polansky G, Du Bose J. Assessment of carcinogenic hazard of chemical mixtures through analysis of binary chemical interaction data. Environ Health Perspect 1994;102(Suppl. 9):113-118.
60. U.S. EPA. Supplemental guidance for conducting health risk assessment of chemical mixtures. Risk Assessment Forum, US E.P.A., Washington, DC. 2000.
61. Krishnan K, Clewell HJI, Andersen ME. Physiologically based pharmacokinetic analysis of simple mixtures. Environ Health Perspectives 1994;102:151-155.
62. Yang RSH, El-Masri HA, Thomas RS, Constan AA. The use of physiologically-based pharmacokinetic pharmacodynamic dosimetry models for chemical mixtures. Toxicol Lett 1995;82-83:497-504.
63. Simmons JE. Application of physiologically based pharmacokinetic modelling to combination toxicology. Food Chem Toxicol 1996;34(11-12):1067-1073.
64. Dobrev ID, Andersen ME, Yang RS. In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ Health Perspect 2002;110(10):1031-1039.
65. Haddad S, Tardif R, Charest-Tardif G, Krishnan K. Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. Toxicol Appl Pharmacol 1999;161(3):249-257.
66. Haddad S, Charest-Tardif G, Tardif R, Krishnan K. Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol Appl Pharmacol 2000;167:199-209.
67. Haddad S, Beliveau M, Tardif R, Krishnan K. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol Sci 2001;63(1):125-131.
68. Haddad S, Krishnan K. Physiological modeling of toxicokinetic interactions: Implications for mixture risk assessment. Environ Health Perspect 1998;106(Suppl. 6):1377-1384.
69. Blancato JN, Chiu N. Predictive modeling for uptake and tissue distribution from human exposures. In: Safety of Water Disinfection: Balancing Chemical & Microbial Risks (G. Craun, Ed.), ILSI Press, Washington, D.C., 1993.
70. Lévesque B, Ayotte P, Tardif R, Ferron L, Gingras S, Schlouch E, Gingras G, Levallois P, Dewailly E. Cancer risk associated with household exposure to chloroform. J Toxicol Environ Health Part A, 2002;65:489-502.
71. Health Canada. Trihalomethanes in drinking water. Document for public comment. Federal-Provincial-Territorial Committee on Drinking Water, Ottawa, ON. 2004. http://www.hc-sc.gc.ca/hecs-sesc/water/pdf/trihalomethanes-drinking. water.pdf.
72. Bogan KT, Hall LC, Perry L, Fish R, Mckone T, Dowd P, Patton SE, Mallon B. Health risk assessment of trichloroethylene (TCE) in California drinking water: Environmental Sciences Division, Lawrence Livermore National Laboratory, University of California, Livermore, CA, 1988.
73. Weisel CP, Jo WK. Ingestion, Inhalation and dermal exposures to chloroform and trichloroethene from tap water. Environ Health Perspect 1996;104:48-51.
74. Lindstrom AB, Pleil JD. A methodological approach for exposure assessment studies in residence using volatile organic compound-contaminated water. J Air Waste Manage Assoc 1996;46(11):1058-1066.
75. Health Canada. Trichloroethylene in drinking water. Document for public comment. Federal-Provincial-Territorial Committee on Drinking Water, Ottawa, ON. 2004; http://www.hc-sc.gc.ca/hecs-sesc/water/pdCTCE-Consultation.pdf